Ebglyss Injection, Solution
NDC Package 0002-7797-11

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Ebglyss (lebrikizumab-lbkz) injection is eBGLYSS is indicated for the treatment of adults and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. This formulation utilizes a injection, solution delivery system. Marketed by Eli Lilly And Company, this product is identified by NDC 0002-7797 and is authorized under FDA application BLA761306.

Identification & Billing

NDC Package Code
0002-7797-11
Package Description
1 SYRINGE in 1 CARTON / 2 mL in 1 SYRINGE (0002-7797-01)
Product Code
0002-7797
11-Digit Billing Format
00002779711
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Ebglyss
Non-Proprietary Name
Lebrikizumab-lbkz
Substance Name
Lebrikizumab
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
LEBRIKIZUMAB 250 mg/2mL
Pharmacologic Class
Usage Information
EBGLYSS is indicated for the treatment of adults and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids.

Regulatory & Marketing

Labeler Name
Eli Lilly And Company
Product Type
Human Prescription Drug
FDA Application #
BLA761306
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
09-13-2024
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0002-7797). Click a package code to view its specific billing and regulatory data.

0002-7797-61
1 SYRINGE in 1 CARTON / 2 mL in 1 SYRINGE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0002-7797-11 identifies a specific commercial package of 1 syringe in 1 carton / 2 ml in 1 syringe (0002-7797-01) of Ebglyss, a human prescription drug labeled by Eli Lilly And Company. This injection, solution is formulated for subcutaneous use and contains lebrikizumab as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Eli Lilly And Company on September 13, 2024. The current certification is valid through December 31, 2027.

How is this Eli Lilly And Company product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00002779711. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0002-7797-11
11-Digit CMS (5-4-2)
00002-7797-11

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.